新药研发中的风险管理与药物经济学研究投入

新药研发过程中存在固有的风险，并且在近年来有日趋增加的趋势。企业的决策者必须采取适当的措施控制新药研发过程中的风险，以实现自身及股东的效用最大化。其中在新药研发过程中进行药物经济学研究是一种风险控制手段，它具有独特的优势。通过期望效用模型，我们发现药物经济学研究能够创造价值，同时还能估算出药物经济学研究的最优投入水平。

Risk Management and Investment in Pharmacoeconomies Study in New Drug R&D

R＆D process of new drugs contains inherent risks, which have the trend of increasing in recent years. In order to achieve their own and the shareholders＇ utility maximization, enterprise decision-makers must take appropriate measures to control the risks of R＆D process of new drugs. In the process of new drug R＆D, pharmacoeconomics study is a means of risk control, which has unique advantages. Through the expected utility model, we found that the pharmacoeconomics study can create the value of economics, but also can be estimated the optimal investment in pharmacoeconomics study.